Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Sigma non-opioid intracellular receptor 1 (Sigma-1 receptor, SIGMAR1) is a unique, ligand-regulated transmembrane chaperone protein primarily localized at the mitochondria-associated endoplasmic reticulum membrane (MAM). It plays a critical role in maintaining cellular homeostasis by modulating calcium signaling, endoplasmic reticulum (ER) stress responses, lipid transport, and the trafficking and activity of various ion channels and G-protein-coupled receptors. Originally misclassified as an opioid receptor, the Sigma-1 receptor is now recognized as a distinct, highly conserved protein with no sequence homology to other mammalian receptors. It is widely expressed in the central nervous system, where it is implicated in neuroprotection, synaptic plasticity, and cell survival.
Dysfunction of the Sigma-1 receptor is associated with several neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), neuropathic pain, depression, and drug addiction. It is also implicated in cancer cell proliferation. The receptor is highly sensitive to various exogenous ligands, with haloperidol acting as a classic high-affinity antagonist. Therapeutic strategies targeting the Sigma-1 receptor include agonists like pridopidine and blarcamesine, which aim to enhance neuroprotection and restore neuronal homeostasis, as well as antagonists like E-52862 (S1RA), which are developed for pain management and the potentiation of opioid analgesia.
Sigma-1 receptor agonism (which enhances chaperone activity, restores calcium homeostasis, and promotes neuroprotection) and Sigma-1 receptor antagonism (which blocks chaperone activity, modulates neurotransmitter release, and alleviates neuropathic pain).
14 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sigma non-opioid intracellular receptor 1 (SIGMAR1) (SIGMAR1).